<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016639</url>
  </required_header>
  <id_info>
    <org_study_id>Version1</org_study_id>
    <nct_id>NCT01016639</nct_id>
  </id_info>
  <brief_title>Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer</brief_title>
  <acronym>CORGI</acronym>
  <official_title>Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose with this study is to evaluate treatment with radio chemotherapy (oxaliplatin and
      capecitabine) given concommitant with radiotherapy in patients with gastrointestinal tumors.
      The trial consists ot two separate studies; CORGI-U in patients with stomach- bile ducts-
      gallbladder and pancreas cancer, and CORGI-L in patients with colorectal cancer.

      CORGI-U will be designed as a phase-I-II-study,in which the first part will be a chemotherapy
      dose finding study, followed by a phase II part to establish response rates. All subjects
      receives radiotherapy concommitant.

      CORGI-L is a phase II trial, in which patients are treated with chemotherapy at fixed doses
      with radiotherapy concommitant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Stomach Cancer</condition>
  <condition>Gall Bladder Cancer</condition>
  <condition>Bile Ductus Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oxaliplatin, capecitabine, radiotherapy</intervention_name>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years of age

          -  Measurable disease according to RECIST

          -  ECOG Performance Status 0-1

          -  ANC over 1.5 x 10 9/L

          -  Platelets over 100 x 10 9/L

          -  Creatinine less than 1.5 x ULN

          -  Bilirubin less than 1.5 x ULN

          -  ALT less than 2.5 x ULN

          -  Signed informed concent

        Exclusion Criteria:

          -  Prior radiotherapy to the same local

          -  Prior chemotherapy for locally advanced or metastatic disease

          -  Pregnancy or breast feeding

          -  Peripheral neuropathy more than grade 1

          -  Uncontrolled diarrhéa

          -  Other serious uncontrolled concomitant illness

          -  Lymph node metastasis that can not be included in the GTV (gross tumor volume),
             without exceeding the stipulated radiotherapy doses in organs at risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Johnsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Lund</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centralsjukhuset, Dept of Oncology</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Malmö, Dept of Oncology</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>October 14, 2011</last_update_submitted>
  <last_update_submitted_qc>October 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stomach cancer</keyword>
  <keyword>Gall bladder cancer</keyword>
  <keyword>Bile ductus cancer</keyword>
  <keyword>Pancreas cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Chemo radiotherapy</keyword>
  <keyword>Phase I-II</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

